Give Online: Help shape patient care for generations to come.
Cleveland Clinic Logo


Request an Appointment

Cancer Answer Line:

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

Cancer Clinical Trials Results

CASE 17814 14-1486 Enhanced Recovery after Surgery: A Randomized Control Trial of Perioperative Management of Gynecologic Patients Fairview, Hillcrest, Main Campus  Gynecologic
CASE 981313-662 Sentinal Lymph Node Mapping for Endometrial Cancer Fairview, Hillcrest, Main Campus  Endometrial, Gynecologic
GOG 0225IRB 12-869 Can Diet and Physical Activity Modulate Ovarian or Primary Peritoneal Cancer Progression-Free Survival? Fairview, Hillcrest, Main CampusStage 2, Stage 3, Stage 4 Fallopian Tube, Gynecologic, Ovarian, Peritoneal
GOG 023815-257 A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Fairview, Hillcrest, Main CampusRecurrentPhase 2Endometrial, Gynecologic
GOG 0263CC968 Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy. Fairview, Hillcrest, Main CampusStage 1, Stage 2Phase 3Cervical, Gynecologic
GOG 0264CC906 A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advance Stage and Recurrent Chemo-Naive Sex Cord-Stromal Tumors of the Ovary Fairview, Hillcrest, Main CampusRecurrent, Stage 2, Stage 3, Stage 4Phase 2Gynecologic, Ovarian
GOG 0274CC00194 A Phase III Trial of Adjuvant Chemotherapy as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone. Fairview, Hillcrest, Main CampusStage 1, Stage 2, Stage 3, Stage 4Phase 3Cervical, Gynecologic
GOG 028314-851 A Phase II Trial of DCTD-Sponsored Dasatinib (NSC #732517 IND #73969) in recurrent/persistent ovary, fallopian tube, primary peritoneal, endometrial, or endometriosis-associated clear cell carcinoma characterized for the retention or loss of BAF250a Expression Fairview, Hillcrest, Main Campus Phase 2Gynecologic, Ovarian
GOG 300515-866 A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrentand Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous EpithelialOvarian, Fallopian Tube, or Primary Peritoneal Cancer Fairview, Hillcrest, Main CampusStage 2, Stage 3, Stage 4Phase 3Fallopian Tube, Gynecologic, Ovarian, Peritoneal
GOG 9923853 A Phase I Study of Carboplatin/Paclitaxel/CTEP-Supplied Bevacizumab (NSC #704865, IND #7921) and CTEP-Supplied Agent ABT-888 (NSC#737664, IND #77840) in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube or primary peritoneal cancer Hillcrest, Main CampusStage 2, Stage 3, Stage 4Phase 1Fallopian Tube, Gynecologic, Ovarian, Peritoneal
JAN 1814 14-711 A Randomized, Open-Label Study Comparing the Combination of YONDELIS, and DOXIL/CAELYX,With DOXIL,/CAELYX, Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Fairview, Hillcrest, Main CampusRecurrentPhase 3Fallopian Tube, Gynecologic, Ovarian, Peritoneal
MORAb-003-011 15-298 MORAb-003-011, A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer Fairview, Hillcrest, Main CampusRecurrentPhase 2Fallopian Tube, Gynecologic, Ovarian, Peritoneal

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).


Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.